Hypertension, medications, and risk of severe COVID-19: A Massachusetts community-based observational study.

The Journal of Clinical Hypertension
Ann Z BauerDavid Kriebel

Abstract

It remains uncertain whether the hypertension (HT) medications angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) mitigate or exacerbate SARS-CoV-2 infection. We evaluated the association of ACEi and ARB with severe coronavirus disease 19 (COVID-19) as defined by hospitalization or mortality among individuals diagnosed with COVID-19. We investigated whether these associations were modified by age, the simultaneous use of the diuretic thiazide, and the health conditions associated with medication use. In an observational study utilizing data from a Massachusetts group medical practice, we identified 1449 patients with a COVID-19 diagnosis. In our study, pre-infection comorbidities including HT, cardiovascular disease, and diabetes were associated with increased risk of severe COVID-19. Risk was further elevated in patients under age 65 with these comorbidities or cancer. Twenty percent of those with severe COVID-19 compared to 9% with less severe COVID-19 used ACEi, 8% and 4%, respectively, used ARB. In propensity score-matched analyses, use of neither ACEi (OR = 1.30, 95% CI 0.93 to 1.81) nor ARB (OR = 0.94, 95% CI 0.57 to 1.55) was associated with increased risk of severe COVID-19. Thiazide...Continue Reading

References

Aug 24, 1999·American Journal of Epidemiology·M M Joffe, P R Rosenbaum
May 29, 2004·Trends in Pharmacological Sciences·Anthony J TurnerNigel M Hooper
Nov 14, 2008·American Journal of Physiology. Renal Physiology·María José SolerDaniel Batlle
Apr 4, 2009·Journal of the American Society of Hypertension : JASH·Jewell A JessupCarlos M Ferrario
May 15, 2015·American Journal of Hypertension·Giselle SarganasHannelore K Neuhauser
Apr 16, 2016·Circulation Research·Vaibhav B PatelGavin Y Oudit
Nov 1, 2017·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·Massimo VolpeKostantinos Tsioufis
Mar 5, 2020·Drug Development Research·David Gurwitz
Mar 15, 2020·The Lancet. Respiratory Medicine·Lei FangMichael Roth
Mar 28, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Thomas C HanffAmir M Mohareb
Apr 23, 2020·JAMA : the Journal of the American Medical Association·Safiya RichardsonTheodoros P Zanos
May 2, 2020·The New England Journal of Medicine·Giuseppe ManciaGiovanni Corrao
May 2, 2020·The New England Journal of Medicine·Harmony R ReynoldsJudith S Hochman
May 8, 2020·Proceedings of the National Academy of Sciences of the United States of America·Jian ShangFang Li
May 12, 2020·Clinical Hypertension·Sungha ParkUNKNOWN Korean Society of Hypertension
May 30, 2020·Critical Care Medicine·Toshiaki IbaJecko Thachil
Jun 1, 2020·Diabetes & Metabolic Syndrome·Awadhesh Kumar Singh, Ritu Singh
Jun 3, 2020·Thrombosis Research·Fatimah Al-AniAlejandro Lazo-Langner
Jun 5, 2020·Turkish Journal of Medical Sciences·Hakan GökerSerhat Ünal
Jun 20, 2020·JAMA : the Journal of the American Medical Association·Emil L FosbølLars Køber
Jun 20, 2020·JAMA : the Journal of the American Medical Association·Gregory Curfman

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR

Software Mentioned

SAS

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.